Advances in medical therapy for glaucoma : Current Opinion in Ophthalmology

Secondary Logo

Journal Logo

Advanced Search
GLAUCOMA: Edited by Donald L. Budenz

Advances in medical therapy for glaucoma

Ostler, Erika; Rhee, Douglasa; Burney, Edwarda; Sozeri, Yasemina

Author Information

aDepartment of Ophthalmology and Visual Sciences and University Hospitals Eye Institute, Case Western Reserve University, Cleveland, Ohio, USA

Correspondence to Yasemin Sozeri, MD, Assistant Professor Department of Ophthalmology and Visual Sciences and University Hospitals Eye Institute, Case Western Reserve University, Cleveland, Ohio, USA. Tel: +440 974 4141; e-mail: [email protected]

Current Opinion in Ophthalmology 32(2):p 129-133, March 2021. | DOI: 10.1097/ICU.0000000000000740

Abstract

Purpose of review 

To discuss a new class of medication that has recently become available for the treatment of glaucoma; as well as share insights into developments in glaucoma medicine administration which has the potential to revolutionize medical therapy for glaucoma.

Recent findings 

Newly available eye drops, netarsudil 0.02% and latanoprostene bunod 0.024%, are improving aqueous outflow through the conventional outflow tract. Other new developments in medical glaucoma are focused on alternative methods for sustained glaucoma medication delivery.

Summary 

Newer medications may be able to extend the duration of medically controlled glaucoma, delaying or possibly eliminating the need of glaucoma surgery for some patients. Alternative methods of delivery for glaucoma medications may be a key factor in improving outcomes with currently available medications.

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid